Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
Ebrahimi B, Viswanadhapalli S, Pratap UP, Rahul G, Yang X, Pitta Venkata P, Drel V, Santhamma B, Konda S, Li X, Sanchez ALR, Yan H, Sareddy GR, Xu Z, Singh BB, Valente PT, Chen Y, Lai Z, Rao M, Kost ER, Curiel T, Tekmal RR, Nair HB, Vadlamudi RK. Ebrahimi B, et al. Among authors: viswanadhapalli s. NPJ Precis Oncol. 2024 May 24;8(1):118. doi: 10.1038/s41698-024-00612-y. NPJ Precis Oncol. 2024. PMID: 38789520 Free PMC article.
Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.
Liu X, Viswanadhapalli S, Kumar S, Lee TK, Moore A, Ma S, Chen L, Hsieh M, Li M, Sareddy GR, Parra K, Blatt EB, Reese TC, Zhao Y, Chang A, Yan H, Xu Z, Pratap UP, Liu Z, Roggero CM, Tan Z, Weintraub ST, Peng Y, Tekmal RR, Arteaga CL, Lippincott-Schwartz J, Vadlamudi RK, Ahn JM, Raj GV. Liu X, et al. Among authors: viswanadhapalli s. Nat Cancer. 2024 May 20. doi: 10.1038/s43018-024-00783-4. Online ahead of print. Nat Cancer. 2024. PMID: 38769429 No abstract available.
Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.
Collier AB, Viswanadhapalli S, Gopalam R, Lee TK, Kassees K, Parra K, Sharma G, Reese TC, Liu X, Yang X, Ebrahimi B, Pratap UP, Mahajan M, Arnold WC, Baker A, Chen CY, Elmore ST, Subbarayalu P, Sareddy GR, Valente PT, Kost ER, Ahn JM, Vadlamudi RK. Collier AB, et al. Among authors: viswanadhapalli s. Cancers (Basel). 2024 Jan 24;16(3):500. doi: 10.3390/cancers16030500. Cancers (Basel). 2024. PMID: 38339252 Free PMC article.
The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Spencer N, Rodriguez Sanchez AL, Gopalam R, Subbarayalu P, Medina DM, Yang X, Ramirez P, Randolph L, Aller EJ, Santhamma B, Rao MK, Tekmal RR, Nair HB, Kost ER, Vadlamudi RK, Viswanadhapalli S. Spencer N, et al. Among authors: viswanadhapalli s. Int J Mol Sci. 2023 Dec 13;24(24):17426. doi: 10.3390/ijms242417426. Int J Mol Sci. 2023. PMID: 38139260 Free PMC article.
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP, Jayamohan S, He Y, Alejo S, Johnson JD, Palacios BE, Pratap UP, Chen Y, Liu Z, Zou Y, Lai Z, Suzuki T, Viswanadhapalli S, Weintraub ST, Palakurthi S, Valente PT, Tekmal RR, Kost ER, Vadlamudi RK, Sareddy GR. Venkata PP, et al. Among authors: viswanadhapalli s. Cancer Lett. 2023 Oct 28;575:216383. doi: 10.1016/j.canlet.2023.216383. Epub 2023 Sep 14. Cancer Lett. 2023. PMID: 37714256
Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma.
Pratap UP, Tidwell M, Balinda HU, Clanton NA, Yang X, Viswanadhapalli S, Sareddy GR, Liang D, Xie H, Chen Y, Lai Z, Tekmal RR, McHardy SF, Brenner AJ, Vadlamudi RK. Pratap UP, et al. Among authors: viswanadhapalli s. Mol Cancer Ther. 2023 Nov 1;22(11):1248-1260. doi: 10.1158/1535-7163.MCT-23-0031. Mol Cancer Ther. 2023. PMID: 37493258 Free PMC article.
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.
Altwegg KA, Pratap UP, Liu Z, Liu J, Sanchez JR, Yang X, Ebrahimi B, Panneerdoss DM, Li X, Sareddy GR, Viswanadhapalli S, Rao MK, Vadlamudi RK. Altwegg KA, et al. Among authors: viswanadhapalli s. Breast Cancer Res Treat. 2023 Jul;200(1):151-162. doi: 10.1007/s10549-023-06958-4. Epub 2023 May 18. Breast Cancer Res Treat. 2023. PMID: 37199805 Free PMC article.
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, Chen Y, Jayamohan S, Pratap UP, Clarke K, Zou Y, Lv Y, Weldon K, Viswanadhapalli S, Lai Z, Ye Z, Chen Y, Gilbert AR, Suzuki T, Tekmal RR, Zhao W, Zheng S, Vadlamudi RK, Brenner AJ, Sareddy GR. Alejo S, et al. Among authors: viswanadhapalli s. Neuro Oncol. 2023 Jul 6;25(7):1249-1261. doi: 10.1093/neuonc/noad018. Neuro Oncol. 2023. PMID: 36652263 Free PMC article.
Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
Blankenship L, Pratap UP, Yang X, Liu Z, Altwegg KA, Santhamma B, Ramasamy K, Konda S, Chen Y, Lai Z, Zheng S, Sareddy GR, Valente PT, Kost ER, Nair HB, Tekmal RR, Vadlamudi RK, Viswanadhapalli S. Blankenship L, et al. Among authors: viswanadhapalli s. Cancers (Basel). 2022 Nov 2;14(21):5400. doi: 10.3390/cancers14215400. Cancers (Basel). 2022. PMID: 36358818 Free PMC article.
40 results